BridgeBio Oncology Therapeutics, Inc. 8-K filing
Filed 2026-03-05 · Report date 2026-03-05 · 2026
Filing metadata
- Accession number
- 0001193125-26-093997
- Form type
- 8-K
- CIK
- 0001869105
- Primary document
- https://www.sec.gov/Archives/edgar/data/1869105/000119312526093997/bbot-20260305.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for BridgeBio Oncology Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-145.8M | - | - |
| Net Income | $-134.0M | - | - |
| Eps Basic | -4.3 | - | - |
| Eps Diluted | -4.3 | - | - |
| Cash And Equivalents | $425.5M | - | - |
| Total Assets | $448.4M | - | - |
| Total Liabilities | $37.3M | - | - |
| Shareholders Equity | $411.1M | - | - |